Market Intelligence, Clinical Progress, and High-Purity Reagents for Multiple Myeloma, Solid Tumor, and Hematology Development.
BCAM (Basal Cell Adhesion Molecule, CD239), a member of the immunoglobulin superfamily featuring Ig-like V-type 1, V-type 2, and C2-type domains, is encoded by the BCAM gene (UniProt P50895). Key mutations define the Lutheran blood group antigens (e.g., Lu(a) defined by rs28399653). Limited expression in normal tissues but upregulated in malignant plasma cells and various epithelial tumors makes it an attractive target for ADC, bispecific, and CAR-T therapies.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for BCAM/CD239 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | BCAM/CD239 ECD-Fc Fusion Protein (>95% purity, <1EU/ug endotoxin, sequence verified, HEK293 expressed for native glycosylation) | View BCAM Products |
| Gene Delivery | BCAM/CD239 Promise-ORF / Lentivirus (full-length ORF for stable cell line generation) | View BCAM Products |
| Benchmark Ab | Anti-BCAM (Clinical Benchmark Sequence / SGN-B6A Analog) Recombinant positive control | View BCAM Products |
| Validator | BCAM siRNA Set (for knockdown verification and specificity controls) | View BCAM Products |
| Related Target: LAMA5 | Natural ligand (Laminin alpha-5); adhesion assay pairing & cross-linking validation | View LAMA5 Products |
| Related Target: BCMA | TNFRSF17; established MM target; combination strategies with BCAM | View BCMA Products |
| Related Target: GPRC5D | Emerging MM target with distinct MOA; benchmark for cross-reactivity panels | View GPRC5D Products |
| Related Target: ITGA6 | Integrin alpha-6; laminin co-receptor for counter-screening & combination studies | View ITGA6 Products |
| Related Target: EPCAM | Co-expressed epithelial tumor marker for bispecific strategies | View EPCAM Products |
Critical Assay Challenges & TarMart Advantage
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Laminin-511 Binding Verification | ECD-Fc protein preserves native conformation for ligand binding assays; >95% purity ensures low background in SPR/BLI |
| ADC Internalization Efficiency | High-purity extracellular domain enables quantitative internalization assays (FACS/Imaging) without contaminant interference |
| Cross-species Cyno/Mouse Evaluation | Human/Mouse/Cyno ortholog proteins available with >95% purity; sequence verified for toxicology bridging studies |
| Specificity vs. Immunoglobulin Superfamily | Strictly verified by mass spec to exclude cross-reactivity with structurally related adhesion molecules |
| Glycosylation-dependent Ligand Binding | HEK293 expressed (native glycosylation) preserves laminin-binding conformation |
| Lack of Validated Positive Controls | Clinical Benchmark Antibodies included as highly pure recombinant biosimilars |
| Flow Cytometry Artifacts | Lentivirus-mediated stable cell lines ensure physiologically relevant membrane topology |
Live BCAM/CD239 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for BCAM/CD239 therapeutics is intensifying, driven by its dual role in oncology (as a tumor-associated antigen in multiple myeloma, ovarian, breast, and other solid tumors) and hematology (mediating red blood cell adhesion in Sickle Cell Disease). Major players are shifting focus from traditional mAbs to Antibody-Drug Conjugates (ADCs) to exploit BCAM's rapid internalization. As first-generation therapies (e.g., SGN-B6A from Pfizer/Seagen) enter clinical trials, the next wave of R&D is targeting combination regimens (with IMiDs, checkpoint inhibitors), bispecific approaches, and precise ligand-blocking therapies for sickle cell patients. BCAM represents a next-generation surfaceome target for antigen-heterogeneous patient populations, with limited normal tissue distribution.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| ADC | Pfizer (Seagen), Emerging Biotechs | Multiple Myeloma (RRMM), Solid Tumors (Ovarian, Breast) | Internalization Assay (Need high-purity ECD-Fc for binding/internalization correlation; pH-dependent binding screen) |
| Bispecific | Immuno-oncology focused biotechs, Preclinical Pipelines | Relapsed/Refractory MM, Solid Tumors | T-cell engagement validation (Need cell-surface expressed target via Lentivirus); Heterodimer validation (Need cross-reactive Abs & controls) |
| CAR-T | Academic institutions, Cell therapy companies | Post-BCMA failure patients, Hematologic Malignancies | ScFv binding specificity (Need ortholog panels for cross-reactivity); Stable cell line generation (Lentivirus); Flow cytometry controls |
| Monoclonal Antibody | Academic & Pharma Collaborations | Sickle Cell Disease (SCD) | LAMA5 blocking assay (Need native HEK293 folded ECD); Affinity ranking via SPR; cross-species reactivity |
| Small Molecule | Various | Vaso-occlusive crises | Selectivity assay (Need high-purity native receptors) |